u 69593 has been researched along with phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, XM; Fang, Q; Han, ZL; Li, N; Li, XH; Pan, JX; Tang, HH; Wang, P; Wang, R; Wang, ZL; Zheng, T | 1 |
| Chen, D; Fang, Q; Li, N; Niu, J; Shi, X; Shi, Y; Xiao, J; Xu, B; Xu, K; Zhang, M; Zhang, Q; Zhang, R | 1 |
2 other study(ies) available for u 69593 and phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide
| Article | Year |
|---|---|
Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.
Topics: Adamantane; Animals; Benzeneacetamides; Dipeptides; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Injections, Intraventricular; Male; Mice; Naltrexone; Nociception; Oligopeptides; Pyrrolidines | 2014 |
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
Topics: Analgesics, Opioid; Animals; Ligands; Male; Mice; Neuralgia; Peptides, Cyclic; Receptors, Neuropeptide | 2021 |